To determine whether PIs can act against ERα+ breast cancer cells that have intrinsic resistance to endocrine therapy regimens, the ER+/HER2+ breast cancer cell lines BT474 and MDA-MB-361 were cultured in the presence of various carfilzomib or bortezomib concentrations. Here, ERBB2 is linked to breast carcinoma.